Table 1.

Conditions affecting esx-3 transcription

Treatment*	Transcription change direction	Nominal P value	False discovery rate q value†
111895	Up	0	0.00
Dipyridyl	Up	0	0.00
Deferoxamine	Up	0	0.04
Clofazimine	Up	0	0.04
Ascididemin	Up	0	0.03

Gene set enrichment analysis was performed as described in ref. 26. Expression changes with a nominal P value <0.05 and a false discovery rate q value <0.05 were considered significant.

*Treatments from ref. 27: 111895, dipyridyl, deferoxamine, and ascididemin are known chelators. Clofazimine is an antituberculosis drug with an unknown mechanism of action.

^†False discovery rate q value is the fraction of observations expected to be false positives.